GT719 Injection for Relapsed CD19+ B-cell Cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new injection called GT719 for adults with B-cell cancers that have come back or not responded to treatment. The cancer cells must have a marker called CD19. The study aims to see if the treatment is safe and works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must volunteer and sign a consent form.
- You must be able to follow the study plan.
- Your daily activity level should be good (ECOG score 0 or 1).
- Your cancer cells must have the CD19 marker, confirmed by lab tests.
- You cannot have a weak immune system from birth.
- You must not have had a recent blood clot in your leg or lungs within the last 6 months that needs blood thinners.
- No other medical conditions that would make it hard to test the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new cell therapy called GT719 for people with B-cell leukemia or lymphoma that has not responded to standard treatments. The therapy targets a protein called CD19 on cancer cells, aiming to kill them.
This Phase 2 trial tests whether an injected cell therapy called CNCT19 can treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It may help by targeting specific lymphoma cells, but you must meet several safety and medical eligibility checks.
This trial tests a new treatment called B019 for people whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The treatment targets specific proteins on the cancer cells to help your immune system fight the leukemia.
This trial tests a new antibody drug (GT719) for adults with autoimmune neurological diseases that came back or did not get better with standard treatment. It looks at how safe the drug is and how well it works.
This trial tests if a new cell therapy called GT719 can help people with moderate to severe lupus, inflammatory myopathy, or systemic sclerosis that hasn't gotten better with standard treatments. It aims to find a new option for those who have not responded well to usual medications.
This study tests an investigational cell therapy called GT801 for people whose CD19-positive blood cancer (B-ALL, CLL, or B-NHL) or autoimmune hemolytic anemia (AIHA) has not responded to standard treatments. The therapy is made from your own immune cells, modified to target and destroy cancer cells or abnormal immune cells.
Hear when a new Hematological Malignancy (Leukemia- Lymphoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.